Clinical Trial Update: Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease [Phase 2]

View source ↗

Summary

This Phase 2 trial assessed the safety of single-dose peginesatide in patients with chronic kidney disease. The study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Peginesatide (peginesatide)

Snippet

Sponsor: Affymax | Conditions: Anemia, Chronic Kidney Disease | Phase 2 | Status: TERMINATED